Now that it's steered its way successfully through the treacherous waters of a Phase II/III study for a new-and-improved drug for Parkinson's, Adamas Pharmaceuticals believes this is the right time to mount a $69 million IPO bid as it sets the stage for a pivotal trial.
With IPOs still booming, follow-on financings sizzling and venture capital rolling in at a steady pace, the biotech industry has been stocking up on billions of dollars in cash.
Horizon Discovery Group, which makes and sells tools for genomics research and personalized medicines, has set out to raise about $41.5 million on the AIM market on the London Stock Exchange.
The biotech IPO window is open, and Radius Health is preparing to see if it can make the leap and land on Wall Street with about $86 million in hand.
The antibiotics developer Achaogen has set its terms for a planned IPO, saying it will sell 5 million shares at $12 to $14 a share.
There were a few misfires on the biotech IPO front in the fourth quarter of 2013, but the National Venture Capital Association says it tallied 6 newly minted public drug developers in the period, winding up a big year.
The Woodcliff Lake, NJ-based company tweaks existing injectable drugs to make them preferable to the original therapies and says it is working on 6 advanced development programs with two approved products.
MacroGenics priced its upsized IPO on the high end of its range today, only to see its shares soar more than 50% on the biotech's debut.
A funny thing happened to Fate Therapeutics on its way to the hot biotech IPO market. Following fast on the heels on a pair of breakout IPOs, the offering flopped. And the setback is reigniting a debate over just how long the IPO market can continue to sizzle.
Any jitters about investors' appetite for new biotech IPOs were set aside--at least temporarily--after a trio of companies pushed their way confidently into the market yesterday, raising about $300 million.